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In vitro cytotoxicity and in vivo acute and 7 days repeat-dose
ocular toxicity studies, were conducted in rabbits, in accordance
with the Organisation for Economic Co-operation and Develop-
ment (OECD) guidelines, for bimatoprost loaded nanovesicular
aqueous dispersion (BMT-NV) and its in-situ gelling sub-
conjunctival implant (BMT-NV-IM). For details on the prepara-
tion and evaluation of BMT-NV and its BMT-NV-IM for the control
of glaucoma, please refer to ‘Bimatoprost loaded nanovesicular
long-acting sub-conjunctival in-situ gelling implant: In vitro and
in vivo evaluation’ (Yadav et al., 2019). The in vivo ocular toxicity
was performed only after conﬁrming dermal safety, as required by
OECD. Histological evaluation of various ocular tissues, following
sub-conjunctival implantation with BMT-NV-IM, was done for
ocular tolerance studies.
© 2019 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).j.msec.2019.05.015.
ail.com (M. Yadav), ana.guzman@opt.ucm.es (A. Guzman-Aranguez),
sidhu19@hotmail.com (M. Singh), jogasingh.pharma@gmail.com (J. Singh),
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Speciﬁcations Table
Subject area Pharmacology, Toxicology and Pharmaceutical Sciences
More speciﬁc subject area Nanotechnology
Type of data Table
Image
Text ﬁle
How data was acquired Plate reader (BioTek, Winooski, VT, USA), morphological examination and microscopy
Data format Raw, Analyzed
Experimental factors Cell proliferation cytotoxicity (MTT assay) studies were conducted in vitro using various cell
lines. In vivo acute and 7 days repeat-dose ocular toxicity studies were conducted in rabbits,
in accordance with the OECD guidelines after instillation of bimatoprost loaded
nanovesicular aqueous dispersion (BMT-NV) and its in-situ gelling sub-conjunctival implant
(BMT-NV-IM).
Experimental features % Viability of stratiﬁed HCLE (human corneal - limbal epithelial), HCjE (human conjunctival
epithelial) and R28 (retinal neuronal) cells was determined, after exposure to various
formulations, taking viability of untreated control cells as 100%. For in vivo toxicity studies
treated rabbit eyes were observed for clinical signs of irritation, inﬂammation, or infection,
for the suggested period of study. Safety was also conﬁrmed by observing histological
structure and integrity of the rat eye, at 2 days, 1 week, 1 month and 2-month post
administration of the formulations.
Data source location Nanotechnology lab, University Institute of Pharmaceutical Sciences, Panjab University,
Chandigarh, India
Data accessibility Data is with this article
Related research article Author's name: Monika Yadav, Ana Guzman-Aranguez, Maria J Perez de Lara, Mandeep
Singh, Joga Singh, Indu Pal Kaur
Title: Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling
implant: In vitro and in vivo evaluation.
Journal: Materials Science and Engineering: C
DOI: doi.org/10.1016/j.msec.2019.05.015
Value of the data
 Work describes two-tier safety evaluation of novel nanovesicular ocular drops and a conjunctival in situ-gelling implant of
bimatoprost for use in control of glaucoma.
 In vitro cytotoxicity studies conducted in human corneal limbal epithelial (HCLE), human conjunctival epithelial (HCjE),
and human retinal (R28) cell lines at two to three doses indicated that encapsulation of BMT into nanovesicular system
was safe and could improve the safety over marketed BMT drops.
 In vivo dermal toxicity studies (preamble to ocular toxicity) and acute and repeat dose ocular toxicity studies as per OECD
guidelines also established complete safety of the developed formulation
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1.1. BMT loaded nanovesicles (BMT-NVs) and their incorporation into a gel (BMT-NV-GEL)
BMT-NVs and BMT-NV-GEL was prepared as discussed in the main article [1].
1.2. Cytotoxicity studies
All ingredients employed for preparing the BMT-NV-GEL were of biodegradable and biocompatible
nature and were indicated to be safe for ocular use at the employed concentration. Poloxamer 407
(P407) and carbopol 934P have been already used in FDA approved ophthalmic formulations [2].
Both BMT-NV and BMT-NV-GEL were safe and did not show any statistically signiﬁcant (p < 0.001)
cytotoxicity (Fig. 1, Tables S1eS6 (raw data for Fig. 1, added as supplementary data)) when adminis-
tered to HCLE (150 mg/ml), HCjE (1.5, 15) and R28 (1.5, and 15 mg/ml) cell lines for 24 h. Since BMT-NV-
GEL is to be used as in-situ gelling ocular drops as well as subconjunctival implant so both HCLE and
HCjE cell lines were used. However exposure to high concentration of 150 mg/ml in case of conjunctival
cell lines HCjE showed signiﬁcant cytotoxicity. It may be noted that we expect a slow release from the
Fig. 1. % cell viability in HCLE (a), HCjE (b) and R28 (c) cells at varying concentration after incubation for 24 h. All values are similar
(p < 0.001) except those marked*.
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lower doses i.e 1.5 and 15 mg/ml show complete protection. It may also be noted that exposure of HCjE
cells to 150 mg/ml of free BMT is also toxic (~10% viability; Table S4). In comparison BMT NV and BMT
NV gel are 4 times less toxic (~40% viability; Table S4).
Lower concentrations were also used for R28 cell lines which showed no cytotoxicity at 1.5 and 15
mg/ml.
Marketed drops (Lumigan drops) showed signiﬁcant cell death in all three cell lines at all con-
centrations, and this result is not surprising as it has been published by other researchers [3e6] that
benzalkonium chloride (BAK), the preservative present in the marketed formulation can induce cell
death in in vitro experiments.1.3. In vivo safety studies in rabbits
OECD 405 recommends that in vivo eye irritation/corrosion test, should be conducted after the
in vivo dermal safety (OECD testing guideline 404) of a product/substance is conﬁrmed (AEI, 2002) [7].
The score for both the (i) acute dermal irritation/corrosion study (compiled in Table 1); and the (ii)
acute eye irritation/corrosion (compiled in Table 2) was zero. This clearly demonstrates a non-irritant/
corrosive nature of BMT-NV-GEL when applied to dermal and ocular tissues (topical instillation), and
hence are concluded to be safe for ocular use.
Repeated instillation acute study was performed in view of the fact that glaucoma requires life long
treatment and will need frequent instillation of developed formulation for effective control of IOP.
Similar studies have been reported by us earlier [8]. The scores obtained from this study (Table 4) also
prove the system to be safe for repetitive ocular use.
Table 1
Acute dermal irritation/corrosion study of BMT-NV-GEL in rabbits.
Skin reactions Time in h Total count
Animal 1 Animal 2 Animal 3
0 1 24 48 72 0 1 24 48 72 0 1 24 48 72
Erythema 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/40
Oedema 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/40
Final total score 0/80
(Scoring 0e4 was done as described in OECD guidelines 404, as per Table 1: Grading of skin reactions, page 7 of [7]).
Table 2
Single instillation acute eye irritation/corrosion study of BMT-NV-GEL in rabbit eye.
Tissue of the eye Time in h Total count
Animal 1 Animal 2 Animal 3
0 1 24 48 72 0 1 24 48 72 0 1 24 48 72
Cornea 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/60
Iris 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/30
Conjunctiva 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/45
Chemosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/60
Grand Total score 0/195
(Scoring was done as deﬁned in OECD guidelines 405 as per Table 1: Grading of ocular lesions (page: 8 of [9]).
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period of one week was also evaluated and BMT-NV-GEL was still found to be safe (Table 3).1.4. Ocular tolerance evaluation
Subconjunctival injection of BMT-NV-GEL implant [8] resulted in the formation of a bleb and
conjunctival hyperemia (mild and transient) in 2 out of 4 injected eyes, which was resorbed completely
within 48 h after injection. All eyes appeared normal and similar to the pre-injected or uninjected eyes
after 48 h. The rats tolerated the procedure well, showing no sign of distress or pain during or
immediately following administration. There were no signs of any irritation, swelling or redness and
infection in any of the injected eye during the study. At the end of the study period, the residual gel was
no longer observed and it is assumed that the gel dissolved completely. Particular attention was
directed toward the sclera and conjunctival tissue surrounding the injection site during histological
examination. The tissue appeared normal and we did not detect any signs of inﬂammation such as
accumulation of macrophages, lymphocytic inﬁltrate, or evidence of giant cells (Fig. 2).Table 3
Repeat instillation (ﬁve times a day) acute eye irritation/corrosion study of BMT-NV-GEL in rabbit eye.
Ocular tissue Scores of rabbit 1 Scores of rabbit 2 Scores of rabbit 3 Score
0 h 1 h 24h 48h 72h 0 h 1 h 24h 48h 72h 0 h 1 h 24h 48h 72h
Cornea 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/60
Iris 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/30
Conjunctiva 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/45
Chemosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/60
Total score 0/195
Scoring was done as described under Table 2.
Table 4
Scores of chronic repeat instillation irritation/corrosion study on BMT-NV-GEL.
Ocular tissue Cornea Iris Conjunctiva Chemosis Score Total Score
rabbit 1 0h 0 0 0 0 0/104 0/312
1d 0 0 0 0
2d 0 0 0 0
3d 0 0 0 0
5d 0 0 0 0
6d 0 0 0 0
7d 0 0 0 0
rabbit 2 0h 0 0 0 0 0/104
1d 0 0 0 0
2d 0 0 0 0
3d 0 0 0 0
5d 0 0 0 0
6d 0 0 0 0
7d 0 0 0 0
rabbit 3 0h 0 0 0 0 0/104
1d 0 0 0 0
2d 0 0 0 0
3d 0 0 0 0
5d 0 0 0 0
6d 0 0 0 0
7d 0 0 0 0
Scoring was done as described under Table 2.
Fig. 2. Optical microscopic pictures showing histological section of (a) naïve conjunctival tissue and conjunctival tissue of eyes post-
treatment (b) 2 days, (c) 1 week, (d) 1 month, and (e) 2 month indicating absence of any untoward reactions.
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2.1. Establishing safety of the developed system
2.1.1. Cytotoxicity studies
Viability of stratiﬁed HCLE (human corneal - limbal epithelial), HCjE (human conjunctival epithelial)
and R28 (retinal neuronal) cells was measured by the cell proliferation assay using MTT (3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells were grown in keratinocyte
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25 mg/ml bovine pituitary extract, 0.4 mM CaCl2, 0.2 ng/mL epidermal growth factor (EGF) and other
suitable antibiotics. For suitable stratiﬁcation and differentiation, the serum-free Invitrogen medium
was replaced (at conﬂuence) with Dulbecco's minimal essential medium (DMEM)/F12 medium, sup-
plemented with 10% calf serum and 10 ng/ml EGF for a period of 7 days [10]. R28 cells were grown in
DMEM (Invitrogen, Carlsbad, CA) supplemented with fetal bovine serum (10%), glutamine (2 mM),
gentamicin (0.21 mM), non-essential amino acids and MEM vitamins (1% each).
HCLE, HCjE and R28 cells were exposed, after stratiﬁcation in DMEM/F12 medium, to various test
samples viz. BMT-NV, Blank-NV, BMT-NV-GEL, Blank-NV-GEL, BMT- SOL and marketed formulation
(Lumigan® 0.03% drops) for 24h. MTT assay was then used to determine cell viability [4]. Fresh MTT
solution (0.5 mg/ml) was added to variously exposed cells and incubated for 2 h at 37 C. The purple
formazan complex released from the cells after lysis was then dissolved in dimethyl sulfoxide.
Absorbance of these samples was read on Gen 5 plate reader (BioTek, Winooski, VT, USA) at 570 nm.
The reading was corrected for background by subtracting the absorbance measured at 690 nm from
that at 570 nm. Themean absorbance value of untreated cells was taken as 100% viability and all results
are expressed as % cell viability compared to these cells. All experiments were repeated three times
(n ¼ 3).
2.1.2. BMT-NV-GEL in vivo safety studies as ocular drops
Safety assessment for ocular application was approved by the Institutional Animals Ethics Com-
mittee, Panjab University, Chandigarh, India (PU/IAEC/S/16/110, dated11/7/2016) and performed as per
the OECD guidelines.
2.1.3. Dermal irritation/corrosion test as per OECD guideline 404 (ADI, 2002) [7]
It is required to perform this test prior to the ocular irritation test. Only those test substances, which
are safe for dermal use, are further instilled in to the rabbit eye for eye irritation test [7].
Six-month-old female albino rabbits, weighing between 1.3 and 1.7 kg, and with intact skin were
used. The dorsal trunk area of rabbits was shaved using hair clippers and a depilatory cream,1 day prior
to the test. To 6-cm2 gauze, 0.5 mg of BMT-NV-GEL was applied uniformly. The gauze was ﬁxed for 4h
on the shaved skin with a non-irritating tape, ensuring complete contact with the skin surface. Care
was taken to apply the gauze on a site away from easy access of the animal bymouth or by limbs and to
ensure that animal may not ingest the patch. The uncovered shaved areawas taken as control. After 4h
of application, the gauze piece was removed, and the site was examined after 1h for any signs of er-
ythema, oedema or redness. The test was initially performed on one rabbit and only proceeded with
the other two animals if no reaction was observed on the ﬁrst animal.
2.1.4. Eye irritation/corrosion test as per OECD guideline 405 (AEI, 2002) [9]
Lower lid of right eye of each rabbit (n ¼ 3) was pulled to create a space in the conjunctival sac and
BMT-NV-GEL (0.1 ml) was administered either once or ﬁve X 0.1 ml instillations were made at 5 min
intervals (for repeat test). Contralateral left eye was taken as the control for each animal. After
instillation, each eye was examined at an interval of 1, 24, 48, and 72 h and scored for any reactions as
described in the OECD guidelines (Table: 1, page: 8, reference: [9]). A chronic repeat dose study
included administration of BMT-NV-GEL (0.1 ml), ﬁve X 0.1 ml instillations at 5 min intervals, every day
for 7 days, to conﬁrm safety of the formulation for long term therapy.
2.1.5. Ocular tolerance evaluation
The effect of BMT-NV-GEL implant on structure and integrity of the administered eye (left) was
determined at 2 days, 1week, 1 month and 2-month post administration. Right eye of all the treated
animals was taken as control. Both the eyeballs were incised after sacriﬁcing the animals and washed
with saline. Then they were ﬁxed in 8% w/w formalin solution and dehydrated in an alcohol gradient.
After this the eyeballs were put in melted parafﬁn, which was then solidiﬁed to form a block. Cross-
sections (<5 mm) cut from the latter, were observed microscopically (Nikon eclipse 90i, Japan), after
haematoxyline and eosine (H and E) staining, for any pathological alterations [11].
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